BTIG maintains Buy rating on Haemonetics, $130 target
BTIG maintained its Buy rating on Haemonetics and kept a $130.00 price target.
Story updates
06:28:32 PM UTC
SquawkNews
Ratings actions from Benzinga: GMT) Haemonetics Price Target Raised to $130.00/Share From $110.00 by BTIGRatings actions from Benzinga